Your session is about to expire
← Back to Search
Riluzole + Sorafenib for Melanoma
Study Summary
This trial is testing the combination of two drugs, sorafenib tosylate and riluzole, to treat patients with solid tumors or melanoma. The goal is to find the best dose of sorafenib tosylate that can be given with riluzole, and to learn about any side effects of the combination treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't had any major abdominal issues like a fistula, perforation, or abscess in the last 6 months.My brain lesions were treated, I'm stable for 4 weeks, not on steroids or certain seizure meds.Your kidney function, as measured by creatinine levels, is normal or only slightly elevated.I need medication for irregular heartbeats.I have not had a serious lung bleeding event in the last 4 weeks.I have not had severe bleeding in the last 4 weeks.I've waited the required time after my last cancer treatment or surgery before joining this study.My heart condition is stable, and I haven't had a heart attack in the last 6 months.My blood pressure is not controlled, even with medication.You have enough infection-fighting white blood cells in your body.Your platelet count is at least 100,000 per microliter.I have serious blood vessel problems in my arms or legs.I do not have a serious infection worse than a moderate level.I am on Lovenox for blood thinning, not warfarin.My cancer can be measured or observed.Your AST and ALT levels in the blood are not more than 2.5 times the normal limit.I have a history of bleeding disorders.I have a serious wound or fracture that is not healing.You have trouble swallowing pills.I am allergic to riluzole or sorafenib.I have had a stroke in the last six months.My doctor is reviewing my medications that may affect the trial.I haven't had a heart attack, severe heart disease, stroke, or blood clots in the last 6 months.I have not had major surgery or a significant injury in the last 4 weeks.I can take care of myself but might not be able to do heavy physical work.I expect to need a major surgery during the study.My cancer is not responding to standard treatments, or there are none available for me.Your international normalized ratio (INR) blood test result should be within a certain range.I have HIV or active hepatitis B or C.I have issues absorbing nutrients from my food.I have not used riluzole or sorafenib if I'm in the study's expansion phase and my tumor can be biopsied.Your bilirubin level is not higher than the normal range set by the hospital.
- Group 1: Treatment (riluzole and sorafenib tosylate)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What other investigations have explored the use of Pharmacological Study?
"Currently, 66 trials focused on Pharmacological Study are in progress. 24 of those ongoing research efforts have reached the third phase while 2678 facilities around the world are running studies related to this medication. The majority of these sites can be found in Taibei, Taiwan."
What conditions is Pharmacological Study typically used to treat?
"Pharmacological Study is most often prescribed for progressive, metastatic radioactive iodine-refractory differentiated thyroid carcinoma (dtc). Additionally, it has seen success when employed to treat gastrointestinal stromal tumors, hemangiosarcoma and leiomyosarcoma."
Has the Pharmacological Study received regulatory acceptance from the FDA?
"With limited clinical evidence on its safety and efficacy, the pharmacological study received a rating of 1."
Are there still openings for individuals to participate in this research?
"The information presented on clinicaltrials.gov confirms that this trial, which began posting in February of 2011 and was last updated in September 2022, is no longer recruiting participants. Despite this conclusion, there are numerous other medical studies currently searching for volunteers to join their trials."
How many participants are taking part in this investigation?
"This trial has reached its recruitment cutoff, having been initially posted on February 18th 2011 and last updated on September 15th 2022. Those interested in participating in a clinical study can refer to the 3104 cancer trials or 66 Pharmacological Studies currently seeking participants."
Share this study with friends
Copy Link
Messenger